RxDoctor Payments Data

Daniela Carlos Pons, MD

Urogynecology and Reconstructive Pelvic Surgery · Guaynabo, PRNPI 1043537145

Payments from drug & device makers

$1,947in general payments, 2019–2025

Across 34 payments — averaging $57.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$698
  • Boston Scientific$421
  • BD$204
  • AbbVie$196
  • Axonics, Inc.$121
  • Johnson & Johnson$100
  • plus $207 from 4 others

What the payments were for

  • Food & beverage$1,947100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic19$698
Boston Scientific5$421
BD2$204
AbbVie(2 entities)2$196
Axonics, Inc.1$121
Johnson & Johnson1$100
Smith+Nephew1$87
Intuitive Surgical1$75
Applied Medical Resources Corporation1$28
Pfizer Pharmaceuticals LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$44,868
Medicare patients
99
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron566$272,254
Estradiol803$68,855
PremarinEstrogens, Conjugated71$31,448
Tolterodine Tartrate ErTolterodine Tartrate187$13,192
Trospium Chloride ErTrospium Chloride96$11,526
GemtesaVibegron15$7,436
Methenamine Hippurate152$6,705
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst150$3,339
NitrofurantoinNitrofurantoin Macrocrystal54$2,293
Fosfomycin Tromethamine17$1,958
Clobetasol Propionate27$1,605
Metronidazole15$1,280
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip29$815
Trospium Chloride11$559
Solifenacin Succinate20$526

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Guaynabo

Where these figures come from

Is this you, or does something look wrong? →